[1]王宪,李珂瑶,岳淑珍,等.影响婴幼儿肝血管瘤治疗选择的因素分析[J].临床小儿外科杂志,2021,20(05):437-440,446.[doi:10.12260/lcxewkzz.2021.05.008]
　Wang Xian,Li Keyao,Yue Shuzhen,et al.Treatment selection and influencing factors of infantile hepatic hemangioma[J].Journal of Clinical Pediatric Surgery,2021,20(05):437-440,446.[doi:10.12260/lcxewkzz.2021.05.008]
点击复制

影响婴幼儿肝血管瘤治疗选择的因素分析

《临床小儿外科杂志》[ISSN:1671-6353/CN:43-1380/R] 卷: 第20卷 期数: 2021年05期 页码: 437-440,446 栏目: 儿童肿瘤 出版日期: 2021-05-25
Title:
Treatment selection and influencing factors of infantile hepatic hemangioma
作者:
王宪1;  李珂瑶2;  岳淑珍2;  汤建萍2
1. 南华大学儿科学院(湖南省长沙市, 410007);
2. 湖南省儿童医院皮肤科(湖南省长沙市, 410007)
Author(s):
Wang Xian1;  Li Keyao2;  Yue Shuzhen2;  Tang Jianping2
1. College of Pediatrics, Nanhua University(Changsha, Hunan, 410007);
2. Department of Dermatology, Hunan Children’s Hospital(Changsha, Hunan, 410007)
关键词:
血管瘤/药物疗法; 血管瘤/外科学; 普萘洛尔/投药与剂量; 普萘洛尔/治疗作用; 婴儿
Keywords:
Hemangioma/DT; Hemangioma/SU; Propranolol/AD; Propranolol/TU; Infant
分类号:
R732.2;R726
DOI:
10.12260/lcxewkzz.2021.05.008
摘要:
目的 探讨婴幼儿肝血管瘤治疗方案选择的影响因素。方法 回顾性分析湖南省儿童医院2013年1月至2020年7月诊治的103例婴幼儿肝血管瘤病例资料。按照治疗方法分为口服普萘洛尔组、外科治疗组（口服普萘洛尔组、外科治疗组统称为治疗组）和门诊观察组3组，比较3组的疗效、安全性，并分析婴幼儿肝血管瘤患者需要接受治疗的相关因素。结果 治疗组（66例）和门诊观察组（37例）总有效率分别为84.84%和59.46%；痊愈率分别为66.66%和32.43%，治疗组疗效明显优于门诊观察组（χ2=12.4，P<0.05）。口服普萘洛尔组（49例）和外科治疗组（17例）总有效率分别为79.59%和100%，痊愈率分别为61.22%和82.35%，外科治疗组疗效高于口服普萘洛尔组（χ2=2.771，P<0.05）。多发型和弥漫型肝血管瘤（OR=3.085，95%CI：1.250~7.609）、合并皮肤血管瘤（OR=18.163，95%CI：14.120~23.548）、肝功能异常（OR=0.345，95%CI：0.143~0.836）、血管内皮生长因子升高（OR=2.362，95%CI：1.089~3.265）是婴幼儿肝血管瘤需要接受治疗的独立影响因素（P<0.05）。结论 口服普萘洛尔或外科手术治疗婴幼儿肝血管瘤均安全有效，口服普萘洛尔是治疗多发型或弥漫型肝血管瘤的一线治疗方案。出现多发型和弥漫型肝血管瘤、合并皮肤血管瘤、肝功能异常、血管内皮生长因子升高时，提示患者需要接受治疗。
Abstract:
Objective To investigate the treatment choice and influencing factors of infantile hepatic hemangioma.Methods Retrospective analysis was made on the case data of 103 children with infantile hepatic hemangioma(IHH) treated in Hunan Children’s hospital from January 2013 to July 2020.According to the treatment methods,they were divided into three groups:oral propranolol group,surgical treatment group and outpatient observation group.The efficacy and safety of the three groups of cases were compared and analyzed,and univariate and multivariate analyses were performed by Logistic regression to explore the predictive influencing factors for the treatment of children with IHH.Results The total effective rates of the treatment group (66 cases) and the outpatient observation group (37 cases) were 84.84% and 59.46%,respectively; the recovery rates were 66.66% and 32.43%,respectively.The curative effect of patients in the treatment group was significantly higher than that of the outpatient observation group (χ2=12.4,P<0.05).The total effective rates of the oral propranolol group (49 cases) and the surgical treatment group (17 cases) were 79.59% and 100%,respectively,and the recovery rates were 61.22% and 82.35%,respectively.The surgical treatment group had higher efficacy than oral propranolol group (χ2=2.771,P<0.05).Multiple and diffuse hepatic hemangioma (OR=3.085,95%CI:1.250~7.609),combined with skin hemangioma (OR=18.163,95%CI:14.120~23.548),abnormal liver function (OR=0.345,95%CI:0.143~0.836),elevated vascular endothelial growth factor (OR=2.362,95%CI:1.089~3.265) is an independent influencing factor that requires treatment for infant hepatic hemangioma (P<0.05).Conclusion Oral propranolol therapy or surgical treatment of infantile hepatic hemangioma is safe and effective.Oral propranolol therapy is the first-line treatment for multiple or diffuse hepatic hemangioma.Multiple and diffuse hepatic hemangioma,combined with cutaneous hemangioma,abnormal liver function,and elevated vascular endothelial growth factor indicate that the patient needs treatment.

参考文献/References:

1 Brown J,Arora R,Sethuraman U.Distributive Shock in a Neonate with Diffuse Infantile Hepatic Hemangioma[J].J Emerg Med,2018,54(1):e1-e3.DOI:10.1016/j.jeme-rmed.2017.09.016.
2 Joshi K,Bolia R,Poddar U,et al.Consumptive Hypothyroidism Due to Diffuse Hepatic Hemangiomas Treated With Propranolol Therapy[J].Indian Pediatr,2020,57(4):366-368.DOI:10.1007/s13312-020-1794-x.
3 Zavras N,Dimopoulou A,Machairas N,et al.Infantile hepatic hemangioma:current state of the art,controversies,and perspectives[J].Eur J Pediatr,2020,179(1):1-8.DOI:10.1007/s00431-019-03504-7.
4 Tsai MC,Liu HC,Yeung CY.Efficacy of infantile hepatic hemangioma with propranolol treatment:A case report[J].Medicine,2019,98(4):e14078.DOI:10.1097/MD.0000000000014078.
5 Zhang XT,Ren WD,Song G,et al.Infantile hepatic hemangiomas associated with high-output cardiac failure and pulmonary hypertension[J].BMC Cardiovasc Disord,2019,19(1):216.DOI:10.1186/s12872-019-1200-6.
6 IacobasI,Phung TL,Adams DM,et al.Guidance Document for HepaticHemangioma (Infantile and Congenital) Evaluation and Monitoring[J].J Pediatr,2018,203:294-300.e2.DOI:10.1016/j.jpeds.2018.08.012.
7 Emad A,Fadel S,El Wakeel M,et al.Outcome of Children Treated for Infantile Hepatic Hemangioendothelioma[J].J Pediatr Hematol Oncol,2020,42(2):126-130.DOI:10.1097/MPH.0000000000001536.
8 杨开颖,彭素华,邱桐,等.口服普萘洛尔治疗婴幼儿肝血管瘤的临床研究[J].临床小儿外科杂志,2020,19(2):145-149.DOI:10.3969/j.issn.1671-6353.2020.02.011. Yang KY,Peng SH,Qiu T,et al.Clinical study of oral propranolol in the treatment of infantile hepatic hemangioma[J].J Clin Ped Sur,2020,19 (2):145-149.DOI:10.3969/j.issn.1671-6353.2020.02.011.
9 杨开颖,彭素华,陈思源,等.婴幼儿肝血管瘤诊治现状[J].临床小儿外科杂志,2020,19(8):746-751.DOI:10.3969/j.issn.1671-6353.2020.08.016. Yang KY,Peng SH,Chen SY,et al.Diagnosis and treatment of infantile hepatic hemangioma[J].J Clin Ped Sur,2020,19 (8):746-751.DOI:10.3969/j.issn.1671-6353.2020.08.016.
10 Yang K,Peng S,Chen L,et al.Efficacy of propranolol treatment in infantile hepatic haemangioma[J].J Paediatr Child Health,2019,55(10):1194-1200.DOI:10.1111/jpc.14375.
11 Yang KY,Feng LW,Chen SY,et al.Progressive infantile hepatic hemangioma not responding to propranolol[J].J Dermatol,2019,46(8):e275-e276.DOI:10.1111/1346-8138.14833.
12 Ernst L,Grabhorn E,Brinkert F,et al.Infantile Hepatic Hemangioma:Avoiding Unnecessary Invasive Procedures[J].Pediatr Gastroenterol Hepatol Nutr,2020,23(1):72-78.DOI:10.5223/pghn.2020.23.1.72.
13 Cavalli R,Buffon RB,De Souza M,et al.Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma:rare complication or incidental finding?[J].Dermatology,2016,224(2):106-109.DOI:10.1159/000337553.
14 Ji Y,Chen S,Xu C,et al.The use of propranolol in thetreat nent of infantile haemangiomas:an updale on potential mechanisms of acion[J].Br J Dermatol,2015,172(1):24-32.DOI:10.111/bjd.13388.
15 Hsi Dickie B,Fishman SJ,Axzizkhan RG.Hepatic vascular tumors[J].Semin Pediar Surg,2014,23(4):168-172.DOI:10.103/j.sempedsurg.2014.06.018.

相似文献/References:

[1]宫济春,罗喜荣,高文忠,等.平阳霉素联合地塞米松注射治疗婴幼儿血管瘤[J].临床小儿外科杂志,2007,6(04):31.
[2]杨开颖,彭素华,邱桐,等.口服普萘洛尔治疗婴幼儿肝血管瘤的临床研究[J].临床小儿外科杂志,2020,19(02):145.[doi:10.3969/j.issn.1671-6353.2020.02.011]
　Yang Kaiying,Peng Suhua,Qiu Tong,et al.Clinical study of oral propranolol treatment of infantile hepatic hemangioma[J].Journal of Clinical Pediatric Surgery,2020,19(05):145.[doi:10.3969/j.issn.1671-6353.2020.02.011]

备注/Memo

收稿日期:2020-11-24。
基金项目:湖南省卫生健康委科研课题（编号：20200341）
通讯作者:汤建萍,Email:jpingtang@126.com

更新日期/Last Update: 1900-01-01